Spotlight on the September 9 Issue
| العنوان: | Spotlight on the September 9 Issue |
|---|---|
| المؤلفون: | Robert A. Gross |
| المصدر: | Neurology. 83:953-953 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | medicine.medical_specialty, Telcagepant, Sleep quality, business.industry, medicine.disease, Placebo, Migraine prophylaxis, Poor sleep, Atrophy, Migraine, Internal medicine, medicine, Neurology (clinical), business, CGRP receptor |
| الوصف: | Patients experiencing 3–14 migraine days during a 4-week baseline were randomized to telcagepant 140 mg, telcagepant 280 mg, or placebo twice daily for 12 weeks. This trial was terminated early due to hepatotoxicity concerns, but available data suggest a possible migraine prophylactic effect. CGRP receptor antagonism may represent a new treatment strategy for migraine prophylaxis. See p. 958; Editorial, p. 954 The authors found that longitudinal measures of atrophy derived from MRI scans were correlated with sleep quality in 143 adults. Poor sleep quality may be a cause or consequence … |
| تدمد: | 1526-632X 0028-3878 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::694d1a906f84970f58205dfb9533dd86Test https://doi.org/10.1212/wnl.0000000000000829Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........694d1a906f84970f58205dfb9533dd86 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1526632X 00283878 |
|---|